

Title (en)
S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF

Title (de)
S1P-REZEPTOR-MODULIERENDE VERBINDUNGEN UND IHRE VERWENDUNG

Title (fr)
COMPOSÉS MODULANT LES RÉCEPTEURS DE LA S1P ET LEUR UTILISATION

Publication
EP 2121648 A2 20091125 (EN)

Application
EP 07753654 A 20070321

Priority
US 2007007044 W 20070321

Abstract (en)
[origin: WO2007109334A2] The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

IPC 8 full level
C07D 307/81 (2006.01); **C07D 405/04** (2006.01); **C07D 405/10** (2006.01); **C07D 405/14** (2006.01); **C07D 409/10** (2006.01); **C07D 409/14** (2006.01); **C07D 413/10** (2006.01); **C07D 417/04** (2006.01); **C07D 417/10** (2006.01); **C07D 471/04** (2006.01); **C07D 491/04** (2006.01)

CPC (source: EP)
A61P 1/00 (2017.12); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 7/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07D 413/10** (2013.01); **C07D 417/10** (2013.01); **C07D 471/04** (2013.01); **C07D 491/048** (2013.01)

Citation (search report)
See references of WO 2007109334A2

Citation (examination)
WO 2007061458 A2 20070531 - PREDIX PHARMACEUTICALS HOLDING [US], et al

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK RS

DOCDB simple family (publication)
WO 2007109334 A2 20070927; **WO 2007109334 A3 20080110**; **WO 2007109334 B1 20080327**; AU 2007227278 A1 20070927; AU 2007227278 B2 20140911; CA 2679980 A1 20070927; EP 2121648 A2 20091125; EP 2364976 A1 20110914; EP 2364976 B1 20141008; JP 2010522162 A 20100701; JP 5191497 B2 20130508; MX 2009010060 A 20100120

DOCDB simple family (application)
US 2007007044 W 20070321; AU 2007227278 A 20070321; CA 2679980 A 20070321; EP 07753654 A 20070321; EP 10016060 A 20070321; JP 2009554496 A 20070321; MX 2009010060 A 20070321